Synergy CHC (SNYR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
1 Apr, 2026Executive summary
2025 was a transitional year with strategic progress, including international expansion, new product launches, and expanded beverage distribution with key partners, setting up for significant growth in 2026.
The international license agreement for U.A.E. and Turkey was terminated due to regional instability, resulting in a $2.5 million revenue reversal, but long-term market interest remains.
A new subsidiary was established in Mexico, with initial shipments to Costco de México and strong early 2026 beverage sales.
Financial highlights
Q4 2025 net revenue was $6.07 million, down 41% year-over-year; excluding license reversal, revenue was $8.97 million, down 12.7%.
Q4 gross margin was 36.6% (63.3% prior year); excluding one-time items, gross margin would have been 68.8%.
Q4 net loss was $14.82 million ($1.35/share) vs. net income of $105,700 ($0.01/share) in Q4 2024; adjusted net loss was $3.35 million.
Full year 2025 revenue was $30.38 million vs. $34.83 million prior year; adjusted revenue was $33.28 million.
Full year net loss was $12.34 million ($1.27/share) vs. net income of $2.12 million ($0.28/share) prior year; adjusted net loss was $3.03 million.
Cash and equivalents at year-end were $2.6 million, up from $687.9 thousand a year ago.
Outlook and guidance
2026 expected to be a foundational growth year for the beverage division, with a $2.5 million run rate already achieved in Q1 and early 2026 gross revenue exceeding $600,000.
TV advertising to resume in 2026, targeting at least a 15% lift in same-store sales.
Gross margin anticipated to remain stable or increase, excluding one-time items.
Focus on executing initiatives in Mexico and growing beverage and supplement businesses.
Management expects 2026 to be a foundational year for scaling the beverage division and expanding national footprint.
Latest events from Synergy CHC
- Stockholders will vote on director elections, equity plan changes, warrant issuance, and a reverse split.SNYR
Proxy filing17 Apr 2026 - Q3 sales fell on rebranding, but profitability, liquidity, and growth plans remain strong.SNYR
Q3 202411 Jan 2026 - All director nominees and key proposals were approved, with results to be filed with the SEC.SNYR
AGM 20256 Jan 2026 - Profitability maintained amid revenue decline; IPO and new launches set stage for 2025 growth.SNYR
Q4 202426 Dec 2025 - Shelf registration for $100M in securities, with $5.69M ATM offering to fund growth and expansion.SNYR
Registration Filing16 Dec 2025 - Annual meeting to vote on directors, auditor, equity plan, and preferred stock authorization.SNYR
Proxy Filing2 Dec 2025 - Stockholders to vote on director elections, auditor, equity plan, and preferred stock authorization.SNYR
Proxy Filing2 Dec 2025 - Shareholders will vote on directors, auditor, equity plan expansion, and preferred stock authorization.SNYR
Proxy Filing2 Dec 2025 - Health and wellness firm targets Nasdaq IPO to fund growth amid strong 2023 results and high debt.SNYR
Registration Filing30 Nov 2025